Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Your Golden Chance for H-1B Lottery Registration - March 2026

Client Alert
February 16, 2026

U.S. Citizenship and Immigration Services (USCIS) will open initial H-1B registration at noon Eastern time on March 4, 2026, and will remain open through March 19, 2026.

$100,000 Fee Not Applicable to Change of Status H-1B Petitions:

If you already reside in the U.S. in a valid nonimmigrant status (F-1, F-2, H-4, J-1, O-1, O-2, TN, etc.), and your employer files an H-1B change of status petition, you will not be subject to the proposed $100,000 fee. This fee is intended to discourage certain overseas registrations/filings and is cost-prohibitive for employers to sponsor workers who do not reside in the U.S.

Further, the new H-1B rule of implementing a weighted selection process will generally favor the allocation of H-1B visas to higher-skilled and higher-paid employees, while maintaining the opportunity for employers to secure H-1B workers at all wage levels. This rule benefits physicians, engineers, and other skilled workers paid in Wage Levels 3 or 4 by increasing their chances of being selected in the H-1B lottery, in addition to advanced U.S. degree selections.

Why This is Significant for U.S.-Based Foreign Nonimmigrants:

If you are currently in the U.S. on F-1 OPT/STEM OPT or another valid nonimmigrant status, this year may offer:

  • Reduced financial barriers for employers sponsoring you.
  • Potentially higher selection probability (especially if you qualify for advanced degree or higher wage levels).

In short, if you legally reside in the U.S., this year is your golden chance of being selected in the H-1B lottery.

If you wish to submit employee names in the H-1B lottery, please contact BMD Member Duriya Dhinojwala at dd@bmdllc.com to discuss your options.  

ImmigrationImmigration LawH-1B
Client Alert

USCIS Policy Change Impacting Work Authorization: Advisory for Employers and Human Resources

December 8, 2025USCIS has issued a policy memorandum pausing immigration benefit processing for individuals from 19 high-risk countries and requiring a re-review of certain previously approved cases. This change may affect work authorization, employment verification, and workforce stability. Employers and HR teams should review impacted employees and update compliance procedures.Client Alert

CMS Releases CY 2026 Medicare Physician Fee Schedule Final Rule with Key Payment and Telehealth Updates

December 4, 2025CMS issued the CY 2026 Medicare Physician Fee Schedule Final Rule on October 31, 2025, with changes effective January 1, 2026. The Final Rule includes increases to the conversion factor, a new efficiency adjustment, updates to practice expense methodology, permanent telehealth policy changes, revised payment for skin substitutes, expanded rules for Part B drugs and biologicals, enhanced policies for Rural Health Clinics and Federally Qualified Health Centers, and new care management and behavioral health services.Client Alert

Ohio Department of Medicaid Updates: Key Changes to Physician Reimbursement Rates in Early Parenthood

December 3, 2025The Ohio Department of Medicaid has proposed amending Ohio Administrative Code Rule related to covered Medicaid reimbursements for physicians. Beginning on January 1, 2026, they are proposing an increase to rates for prenatal care, childbirth, and infant care and provider visits.Client Alert

Name, Image, and Likeness Agreements in Healthcare

November 14, 2025For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.Client Alert

Compounding GLP-1 Drugs - Recent Updates

November 13, 2025Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.
Older posts
Newer posts